Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cnMar 27 04:08 ET

WUXI APPTEC held strong! Achieved 2024 performance guidance, expecting to achieve double-digit growth in revenue this year | Interpretations

In 2024, WUXI APPTEC's revenue and net profit saw a slight decline year-on-year, but it still achieved the performance guidance set at the beginning of last year; Despite the ongoing disturbances from the "Biotechnology Safety Act", customers and Orders still experienced substantial growth in 2024; WUXI APPTEC expects to achieve double-digit growth of 10-15% this year.

cls.cnMar 17 11:44 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

AI helps reduce costs and improve efficiency in drug development. The "AI+Medical" Industry has explosive growth opportunities.

China Post Securities pointed out that the Global market size for AI+Medical industry AI solutions is expected to increase from 13.7 billion dollars in 2022 to 155.3 billion dollars in 2030, with a CAGR of 35.5%, indicating explosive growth opportunities in the industry.

cls.cnFeb 27 19:05 ET

The final ruling has changed! Innovative Medical Management has revised its 2024 performance forecast, with the company accumulating losses of nearly 1.8 billion over six years | Interpretations

① Only a month after the performance forecast for 2024 was disclosed, Innovative Medical Management has revised its performance forecast, with net losses expanding to 0.1 billion yuan - -85 million yuan; ② Innovative Medical Management had made relevant risk warnings in its performance forecast, and the dispute case between Qianhai Excellence and Jianhua Hospital has been heard but not yet ruled; ③ Since 2019, Innovative Medical Management has reported losses for six consecutive years, with a cumulative loss amounting to nearly 1.8 billion yuan.

cls.cnFeb 25 09:10 ET

Targeting the original controlling shareholder Zhong Zhu Group, Zhong Zhu Healthcare Holding initiates multiple lawsuits | Quick read announcement

① This evening, Zhong Zhu Healthcare Holding announced three litigation cases, with a total amount involved of 0.219 billion yuan. ② Since January 22 of this year, there have been six lawsuits in which Zhong Zhu Healthcare Holding has been the plaintiff, related to the company's previous Equity Transfer agreement. ③ The company's former controlling shareholder, Zhong Zhu Group, can be seen in the defendant's seat.

cls.cnFeb 17 09:49 ET